Mucosal immunity and optimizing protection with meningococcal serogroup B vaccines

Trends in Microbiology

Volumn 14, Issue 3, 2006, Pages 120-124

  Heyderman, Robert S ^a   Davenport, Victoria ^a   Williams, Neil A ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; MENINGOCOCCUS VACCINE;

IMMUNIZATION; MENINGOCOCCOSIS; MUCOSAL IMMUNITY; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B;

EID: 33644860337     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2006.01.007     Document Type: Article

References (54)

1. C.L. Trotter Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction Lancet 364 2004 365 367
2. L. Jodar Development of vaccines against meningococcal disease Lancet 359 2002 1499 1508
3. C.L. Vermont Recent developments in vaccines to prevent meningococcal serogroup B infections Curr. Opin. Mol. Ther. 5 2003 33 38
4. B.A. Perkins Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland J. Infect. Dis. 177 1998 683 691
5. J.W. Tappero Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile J. Am. Med. Assoc. 281 1999 1520 1527
6. M. Comanducci NadA, a novel vaccine candidate of Neisseria meningitidis J. Exp. Med. 195 2002 1445 1454
7. J.A. Welsch Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine J. Immunol. 172 2004 5606 5615
8. A.J. Pollard, and C. Frasch Development of natural immunity to Neisseria meningitidis Vaccine 19 2001 1327 1346
9. C.L. Trotter Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination Am. J. Epidemiol. 162 2005 89 100
10. C.G. Whitney Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine N. Engl. J. Med. 348 2003 1737 1746
11. P.T. Heath, and J. McVernon The UK Hib vaccine experience Arch. Dis. Child. 86 2002 396 399
12. C.J. Vindurampulle Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy Vaccine 22 2004 3744 3750
13. S.J. Kent Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIV(SF162P3) Vaccine 23 2005 5009 5021
14. P.G. Coen Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica Int. J. Epidemiol. 29 2000 180 188
15. J.S. Bennett Genetic diversity and carriage dynamics of Neisseria lactamica in infants Infect. Immun. 73 2005 2424 2432
16. D.A. Ala'Aldeen Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination J. Clin. Microbiol. 38 2000 2311 2316
17. S.P. Yazdankhah, and D.A. Caugant Neisseria meningitidis: an overview of the carriage state J. Med. Microbiol. 53 2004 821 832
18. V. Davenport Evidence for naturally acquired T cell-mediated mucosal immunity to Neisseria meningitidis J. Immunol. 171 2003 4263 4267
19. K. Robinson Characterization of humoral and cellular immune responses elicited by meningococcal carriage Infect. Immun. 70 2002 1301 1309
20. E. Wedege Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine Infect. Immun. 71 2003 3775 3781
21. G.R. Jones Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization J. Infect. Dis. 178 1998 451 459
22. E.J. Wiertz T-cell responses to outer membrane proteins of Neisseria meningitidis: comparative study of the Opa, Opc, and PorA proteins Infect. Immun. 64 1996 298 304
23. I. Goldschneider Human immunity to the meningococcus. I. The role of humoral antibodies J. Exp. Med. 129 1969 1307 1326
24. G.L. Dixon Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: interleukin-12 production depends on lipopolysaccharide expression in intact bacteria Infect. Immun. 69 2001 4351 4357
25. T. Al-Bader Activation of human dendritic cells is modulated by components of the outer membranes of Neisseria meningitidis Infect. Immun. 71 2003 5590 5597
26. T.E. Singleton Neisserial porin-induced dendritic cell activation is MyD88 and TLR2 dependent J. Immunol. 174 2005 3545 3550
27. L.S. Taams Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population Eur. J. Immunol. 31 2001 1122 1131
28. M.G. Roncarolo Differentiation of T regulatory cells by immature dendritic cells J. Exp. Med. 193 2001 F5 F9
29. Y. Cong Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora J. Immunol. 169 2002 6112 6119
30. P. Guermonprez Antigen presentation and T cell stimulation by dendritic cells Annu. Rev. Immunol. 20 2002 621 667
31. B.L. Kelsall Dendritic cells at the host-pathogen interface Nat. Immunol. 3 2002 699 702
32. J.L. VanCott Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella J. Immunol. 156 1996 1504 1514
33. K.B. Bamford Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype Gastroenterology 114 1998 482 492
34. R. Borrow Meningococcal surrogates of protection-serum bactericidal antibody activity Vaccine 23 2005 2222 2227
35. O. Perez Immune response induction and new effector mechanisms possibly involved in protection conferred by the Cuban anti-meningococcal BC vaccine Infect. Immun. 69 2001 4502 4508
36. B. Haneberg Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans Infect. Immun. 66 1998 1334 1341
37. R.K. Katial Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine Infect. Immun. 70 2002 702 707
38. F. Oftung Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine Infect. Immun. 67 1999 921 927
39. A. Aase Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease Vaccine 21 2003 2042 2051
40. A.R. Foxwell Mucosal immunization against respiratory bacterial pathogens Expert Rev. Vaccines 2 2003 551 560
41. J. Holmgren, and C. Czerkinsky Mucosal immunity and vaccines Nat. Med. 11 2005 S45 S53
42. K.M. Zangwill, and R.B. Belshe Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination Pediatr. Infect. Dis. J. 23 2004 189 197
43. + T lymphocytes Nat. Immunol. 3 2002 229 236
44. F. Bowe Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin Infect. Immun. 72 2004 4052 4060
45. G. Hartmann CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells Proc. Natl. Acad. Sci. U. S. A. 96 1999 9305 9310
46. J.R. Baldridge Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration Vaccine 18 2000 2416 2425
47. Z. Huo Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin A in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide-CRM197 conjugate vaccine mixed with chitosan Infect. Immun. 73 2005 8256 8265
48. J. Huang A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats Vaccine 23 2004 794 801
49. P.G. Djupesland Bi-directional nasal delivery of aerosols can prevent lung deposition J. Aerosol Med. 17 2004 249 259
50. T. Guthrie Mucosal and systemic T-cell mediated immunity following influenza vaccination in healthy adults J. Infect. Dis. 190 2004 1927 1935
51. C. Vermont, and G. van den Dobbelsteen Neisseria meningitidis serogroup B: laboratory correlates of protection FEMS Immunol. Med. Microbiol. 34 2002 89 96
52. M.C. Maiden, and J.M. Stuart Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination Lancet 359 2002 1829 1831
53. M.A. Diggle, and S.C. Clarke Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines J. Clin. Microbiol. 43 2005 4649 4653
54. Lancellotti, M. et al. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect (in press) DOI:10.1016/j.micinf.2005.06.012